The efficacy and safety of high‐dose amoxicillin‐bismuth‐potassium competitive acid blocker therapy for Helicobacter pylori infection—A pilot study
- 26 October 2025
- journal article
- Published by Wiley in Advances in Digestive Medicine
- Vol. 12 (4)
Abstract
Recent developments in Helicobacter pylori ( H. pylori ) treatment have highlighted the rising resistance to clarithromycin. Conversely, amoxicillin resistance remains relatively low in both first‐line and rescue treatments. Evidence has shown that the effectiveness of high‐dose amoxicillin/proton pump inhibitor dual therapy varies in different countries. The effectiveness of combining high‐dose amoxicillin with potassium‐competitive acid blocker (PCAB) and bismuth as a mono‐antibiotic strategy for H. pylori eradication remains to be determined. To assess the efficacy and safety of a 14‐day regimen combining bismuth, high‐dose amoxicillin, and PCAB (Bap therapy) as both first‐line and rescue treatment for H. pylori infection, and to identify the factors that affect the outcome of this novel therapeutic approach. We conducted a retrospective cohort study of patients with H. pylori infection treated with Bap therapy from January 2021 to March 2024 across four hospitals in Taiwan. The regimen consisted of tripotassium dicitrato bismuthate (300 mg four times daily), high‐dose amoxicillin (750 mg four times daily), and vonoprazan (20 mg twice daily) for 14 days. Patients returned in the second week to assess drug adherence and adverse events. Post‐treatment H. pylori status was assessed at least 4 weeks following Bap therapy. Fifty‐one patients receiving Bap therapy as either first‐line ( n = 45) or rescue treatment ( n = 6) were analyzed. Eradication rates in first‐line treatment were 95.6% (95% confidence interval [CI]: 89.6%–100.0%), 97.7% (95% CI: 93.3%–100.0%), and 100.0% in intention‐to‐treat, modified intention‐to‐treat, and per‐protocol analyses, respectively. For rescue therapy, the corresponding eradication rates were all 100%. Adverse event rates were 6.7% for first‐line and 0% for rescue treatments, with adherence rates of 95.6% and 100%, respectively. Univariate analysis indicated significantly lower eradication rates in patients with poor drug adherence (50% vs. 100%; p = .040), while factors such as smoking, alcohol consumption, clarithromycin, and metronidazole resistance did not influence outcomes. The 14‐day Bap therapy demonstrates high efficacy and safety for both first‐line and rescue treatments of H. pylori infection, making it a potential standard treatment option for H. pylori eradication. This study underscores the importance of adherence to therapy and warrants further research to validate the effectiveness of this mono‐antibiotic approach across different lines of treatment for H. pylori infection.Keywords
This publication has 37 references indexed in Scilit:
- Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized StudyClinical Gastroenterology and Hepatology, 2024
- Helicobacter pylori infectionNature Reviews Disease Primers, 2023
- Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled TrialClinical Gastroenterology and Hepatology, 2018
- Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled TrialAmerican Journal of Gastroenterology, 2017
- ACG Clinical Guideline: Treatment of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2017
- Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialThe Lancet, 2016
- High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori InfectionClinical Gastroenterology and Hepatology, 2015
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trialThe Lancet, 2011
- Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United StatesJournal of Gastroenterology, 2010
- Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype statusClinical Pharmacology & Therapeutics, 2004